Agenus Stock Price, News & Analysis

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology firm, announced Dr. Jennifer Buell's participation in a fireside chat at the Jefferies 2020 Virtual London Healthcare Conference on November 17, 2020, from 4:25 PM - 4:55 PM GMT. This event will highlight the company’s innovative pipeline of immune therapies, including checkpoint antibodies and vaccines aimed at enhancing immune responses against cancer. Interested parties can register for the webinar and access a replay on the Agenus website.

Agenus Inc. (NASDAQ: AGEN) announced a webcast on November 16, 2020, featuring Dr. Steven O’Day and other key figures discussing AGEN1181 and its Ph1 trial results. Dr. O’Day will review initial responses in patients with microsatellite stable disease and implications of Treg depletion. Dr. Jennifer Buell and Dr. Dhan Chand will outline next steps for AGEN1181 and share insights on its other drug programs, including AGEN2373 and AgenT-797. Registration is available online, and a replay will be accessible on the Agenus website post-event.

Agenus Inc. (NASDAQ: AGEN) announced participation in the Virtual SITC 2020 Immuno-Oncology Event hosted by B. Riley on November 12, 2020. Key executives, including Dr. Steven O'Day and Dr. Jennifer Buell, will lead discussions on Next-Gen Checkpoint Inhibitors and Cell Therapy 2.0. The event includes two panels: The first from 1:00 PM to 2:00 PM ET, and the second from 2:00 PM to 3:00 PM ET. Interested parties can access replays via provided conference IDs.

Agenus focuses on immuno-oncology therapies designed to activate immune responses against cancer.

Agenus Inc. announced a triggered $10M milestone payment from Merck, following the advancement of the ILT4 antibody, MK-4830, into a Phase 2 clinical trial. This novel checkpoint antibody aims to target immune-suppressive cells in tumors. The company is eligible for an additional $85 million in milestones and royalties from sales. Merck is currently evaluating MK-4830 in combination with KEYTRUDA® for treating advanced non-small cell lung cancer. Agenus retains a significant portion of milestones and royalties due to its agreements.

Agenus Inc. (NASDAQ: AGEN) presented seven novel clinical programs at the SITC 2020 Annual Meeting. Key highlights include AGEN1181, showing clinical responses in hard-to-treat tumors and the first report of intratumoral Treg depletion. AGEN1777 offers improved immune performance as an Fc-enhanced TIGIT antibody. AGEN2373 demonstrates clinical benefit without liver toxicity. The proprietary VISION platform predicts treatment responses with high accuracy. Overall, these findings support Agenus's commitment to advancing immuno-oncology therapies.

Agenus Inc. has appointed Dr. Steven O'Day as its new Chief Medical Officer, enhancing its leadership as the company advances its pipeline of immuno-oncology therapies. Dr. O'Day brings over 30 years of experience and has been pivotal in the development of checkpoint antibody treatments. His expertise will support Agenus in rapidly developing clinical trials for their lead candidates. Dr. O'Day is set to present data on AGEN1181, a next-generation anti-CTLA-4 molecule, at an upcoming conference. This strategic appointment aims to accelerate innovative cancer treatments.

Agenus Inc. (NASDAQ: AGEN) has initiated the dosing of its first patient with agenT-797, an allogeneic iNKT cell therapy targeting moderate to severe COVID-19. This innovative therapy aims to eliminate the SARS-CoV-2 virus while curbing excessive inflammation. Additionally, the FDA has approved agenT-797 for cancer treatment, and trials for cancer patients are expected to begin soon. Agenus emphasizes its unique combination of therapies and cost-effectiveness in addressing critical health issues.

Agenus Inc. (NASDAQ: AGEN) provided a corporate update alongside its Q3 2020 financial results. The company initiated its rolling BLA filing for Balstilimab, with FDA review in progress. Recent clinical trials show Balstilimab achieving a 19% response rate in PD-L1 positive tumors and a combination with zalifrelimab yielding 27%. The cash balance rose to $114 million, while Q3 net loss was $52 million, a slight increase from $46 million in Q3 2019. Revenues totaled $14.8 million, down from $19.9 million in the prior year. New data on AGEN1181 will be presented at the upcoming SITC meeting.

Agenus Inc. (NASDAQ: AGEN) will announce its Q3 2020 financial results before the market opens on October 29, 2020. A conference call and webcast will follow at 8:30 AM ET for a discussion of the results and corporate update. Agenus specializes in immuno-oncology with an extensive pipeline including checkpoint antibodies, cell therapies, and vaccines aimed at enhancing immune responses to cancer and infections. The call will be accessible via the company’s website.